Sun Pharma, a big company that makes medicines, saw its shares go up by over 1 per cent to Rs 1,267 on December 19. This happened because the company shared some exciting news—it's going to buy about 16.7 per cent of Lyndra Therapeutics, a company from Massachusetts, for $30 million. This deal is expected to be completed by the end of December 2023, but some conditions need to be met.
Sun Pharma says this is a strategic investment, which means they're making this deal on purpose to help develop new and innovative ways of delivering medicines. They want to have access to the special technology that Lyndra Therapeutics has, especially for certain medicines and in specific places. This is a big move for Sun Pharma, showing that they're investing in new technologies and ways of making medicines.
At 9:20 am on the same day, the stock was trading at Rs 1,261, which is a little higher than the previous closing price on the National Stock Exchange (NSE). This marks the third consecutive trading session where Sun Pharma's stock has been going up. In the last six months, the stock has gained over 25 per cent, meaning it's been doing well in the stock market.
Lyndra Therapeutics, the company that Sun Pharma is buying a part of, is based in Massachusetts and is into creating new ways of delivering medicines that you can take by mouth. This is called long-acting oral (LAO) therapies, and it's a fancy way of saying they are working on making medicines that work for a long time after you take them. This kind of technology is quite special.
The deal is expected to be finished by the end of December 2023, but as with any deal, certain things need to happen for it to go through.
Lyndra has been doing well on its own, having raised a total of $260 million from investors and partners. This includes a significant $100 million in non-dilutive grants, which means they got money without having to give away part of their company. On their website, Lyndra proudly shares that they've made quick progress by working on 19 different therapies in the lab and moving forward with four therapeutic products to the clinic. This shows that they're making good progress in turning their ideas into real medicines that can help people.
In summary, Sun Pharma is making a smart move by investing in Lyndra Therapeutics. This not only shows that Sun Pharma is interested in new and innovative ways of making medicines but also gives them access to technology that can be valuable for certain medicines and in specific places. As the deal progresses, it will be interesting to see how this strategic investment benefits both companies and the world of medicine as a whole.
